Ribomic Inc. (4591.T)
Tokyo · JPY · Healthcare · Biotechnology
¥64 (-1.54%) as of
Key statistics
- Market cap
- 3.62B
- Forward P/E
- -1.22
- EPS (TTM)
- -22.85
- Dividend yield
- 0.00%
- 52-week range
- 57.00 – 120.00
- Beta
- 0.27
- Revenue (TTM)
- 7.5M
- Profit margin
- 0.00%
- Volume
- 209.40k
About Ribomic Inc.
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Minato, Japan
- Employees
- 25
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.